Is Eli Lilly Stock Heading for $1,000?

Eli Lilly (NYSE: LLY) just delivered another fantastic quarter, showcasing its impressive growth prospects. The company has been a leader in the growing GLP-1 drug market, with fantastic assets in Mounjaro and Zepbound driving much of its growth in recent years. However, despite its strong growth, the stock has given back gains in recent months and is down from the highs of more than $1,100 that it reached earlier in the year. On Monday, it was trading at around $960. In light of its strong Q1 results, can it get back to $1,000 and potentially hit new highs? Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool